Novavax, Inc. (NASDAQ: NVAX) kicked off on Friday, down -2.91% from the previous trading day, before settling in for the closing price of $12.90. Over the past 52 weeks, NVAX has traded in a range of $3.53-$23.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 513.29%. While this was happening, its average annual earnings per share was recorded 81.38%. With a float of $153.03 million, this company’s outstanding shares have now reached $160.09 million.
Considering the fact that the conglomerate employs 1543 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 59.57%, operating margin of -34.74%, and the pretax margin is -35.11%.
Novavax, Inc. (NVAX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Novavax, Inc. is 4.42%, while institutional ownership is 53.02%. The most recent insider transaction that took place on Sep 18 ’24, was worth 95,331. Before that another transaction happened on Jun 21 ’24, when Company’s Director sold 7,500 for $14.09, making the entire transaction worth $105,675. This insider now owns 61,760 shares in total.
Novavax, Inc. (NVAX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 81.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.90% during the next five years compared to 11.55% growth over the previous five years of trading.
Novavax, Inc. (NASDAQ: NVAX) Trading Performance Indicators
Take a look at Novavax, Inc.’s (NVAX) current performance indicators. Last quarter, stock had a quick ratio of 1.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.77, a number that is poised to hit -0.82 in the next quarter and is forecasted to reach -0.09 in one year’s time.
Technical Analysis of Novavax, Inc. (NVAX)
Compared to the last year’s volume of 10.16 million, its volume of 4.88 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 28.35%. Additionally, its Average True Range was 1.08.
During the past 100 days, Novavax, Inc.’s (NVAX) raw stochastic average was set at 24.42%, which indicates a significant increase from 23.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 104.83% in the past 14 days, which was higher than the 103.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.46, while its 200-day Moving Average is $9.38. Nevertheless, the first resistance level for the watch stands at $12.93 in the near term. At $13.34, the stock is likely to face the second major resistance level. The third major resistance level sits at $13.63. If the price goes on to break the first support level at $12.23, it is likely to go to the next support level at $11.94. Should the price break the second support level, the third support level stands at $11.53.
Novavax, Inc. (NASDAQ: NVAX) Key Stats
The company with the Market Capitalisation of 2.01 billion has total of 140,404K Shares Outstanding. Its annual sales at the moment are 983,710 K in contrast with the sum of -545,060 K annual income. Company’s last quarter sales were recorded 415,480 K and last quarter income was 162,380 K.
